Toward a standard definition and measurement of persistence with drug therapy: Examples from research on statin and antihypertensive utilization

被引:121
作者
Caetano, Patricia A. [1 ]
Lam, Jonathan M. C. [1 ]
Morgan, Steven G. [1 ]
机构
[1] Univ British Columbia, Ctr Hlth Serv & Policy Res, Vancouver, BC V6T 1Z3, Canada
关键词
persistence; adherence; compliance; duration; intensity; administrative health databases; drug utilization;
D O I
10.1016/j.clinthera.2006.09.021
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Long-term utilization of prescription drugs for chronic conditions such as hypertension and/or hypercholesterolemia is a reality for millions of individuals, yet therapies may be discontinued before they can exert their beneficial effect. Several studies have measured the mean duration of therapy (ie, persistence) using administrative health databases. However, the terminology and methodology used for measuring persistence varied across studies, making it difficult to compare persistence rates. Objectives: The objectives of this study were to identify currently used measures of persistence and to propose a standard operational definition for use in administrative database analyses of drug utilization. Methods: MEDLINE was searched for English-language articles published between January 1997 and June 2005 that quantified the concepts of persistence, adherence, compliance, or continuity with statin or antihypertensive therapy using administrative prescription claims databases. The conceptual and operational definitions of persistence used in the identified studies were categorized and applied to prescription-refill data for a hypothetical patient to compare the durations of persistence resulting from each method. Results: Thirty-one articles were identified and reviewed. Few of the studies explicitly stated the conceptual definition of persistence used. Five methods of measuring persistence were identified: anniversary models, minimum-refills models, refill-sequence models, proportion-of-days-covered models, and hybrid models. When these models were applied to data for the hypothetical patient, total persistence with drug therapy ranged from 7 days to > 1 year. Conclusions: There continue to be inconsistencies in the definition of persistence and the methods by which it is measured. A standard operational definition of persistence should be 2-dimensional, quantifying not only the total duration of therapy, but also the intensity of medication-taking within this interval. (Clin Then 2006;28:1411-1424) Copyright (c) 2006 Excerpta Medica, Inc.
引用
收藏
页码:1411 / 1424
页数:14
相关论文
共 37 条
  • [21] A population-based European cohort study of persistence in newly diagnosed hypertensive patients
    Hasford, J
    Mimran, A
    Simons, WR
    [J]. JOURNAL OF HUMAN HYPERTENSION, 2002, 16 (08) : 569 - 575
  • [22] Adherence with statin therapy in elderly patients with and without acute coronary syndromes
    Jackevicius, CA
    Mamdami, M
    Tu, JV
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (04): : 462 - 467
  • [23] Adherence with statin therapy in secondary, prevention of coronary heart disease in veterans administration male population
    Kopjar, B
    Sales, AEB
    Piñeros, SL
    Sun, H
    Li, YF
    Hedeen, AN
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2003, 92 (09) : 1106 - 1108
  • [24] High persistence of statin use in a Danish population: Compliance study 1993-1998
    Larsen, J
    Andersen, M
    Kragstrup, J
    Gram, LF
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (04) : 375 - 378
  • [25] Long term persistence with statin treatment in daily medical practice
    Mantel-Teeuwisse, AK
    Goettsch, WG
    Klungel, OH
    de Boer, A
    Herings, RMC
    [J]. HEART, 2004, 90 (09) : 1065 - 1066
  • [26] Marentette MA, 2002, CAN J CARDIOL, V18, P649
  • [27] Morgan Steven G, 2004, Can J Clin Pharmacol, V11, pe267
  • [28] Patterns of antihypertensive use among patients in the US department of defense database initially prescribed an angiotensin-converting enzyme inhibitor or calcium channel blocker
    Okano, GJ
    Rascati, KL
    Wilson, JP
    Remund, DD
    Grabenstein, JD
    Brixner, DI
    [J]. CLINICAL THERAPEUTICS, 1997, 19 (06) : 1433 - 1445
  • [29] Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention
    Perreault, S
    Blais, L
    Lamarre, D
    Dragomir, A
    Berbiche, D
    Lalonde, L
    Laurier, C
    St-Maurice, F
    Collin, J
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (05) : 564 - 573
  • [30] Sheehy O, 2000, CAN J CARDIOL, V16, P1109